Virbac SA (LON:0NM7)

London flag London · Delayed Price · Currency is GBP · Price in EUR
355.00
+1.00 (0.28%)
At close: Feb 11, 2026
Market Cap2.59B +17.6%
Revenue (ttm)1.23B +7.0%
Net Income114.03M -5.6%
EPS13.61 -5.5%
Shares Outn/a
PE Ratio22.74
Forward PE17.33
Dividend1.24 (0.35%)
Ex-Dividend DateJun 24, 2025
Volume1
Average Volume166
Open362.00
Previous Close354.00
Day's Range353.00 - 358.00
52-Week Range255.00 - 371.50
Beta0.86
RSI49.36
Earnings DateSep 17, 2026

About Virbac

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. It serves veterinarians, farmers, and pet owners. The company was founded in 1968 and is headquartered in Carros, France. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1968
Employees 6,365
Stock Exchange London Stock Exchange
Ticker Symbol 0NM7
Full Company Profile

Financial Performance

In 2024, Virbac's revenue was 1.40 billion, an increase of 12.07% compared to the previous year's 1.25 billion. Earnings were 145.29 million, an increase of 19.78%.

Financial numbers in EUR Financial Statements